Oct 27, 2022

Featuring an interview with Prof Axel Hauschild, including the following topics:

• Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00)
• Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23)
• Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAMseq trial; using targeted therapy after immunotherapy (9:58)
• Relationship between tumor mutational burden and response to targeted therapies and immunotherapies; PD-L1 expression and efficacy of immunotherapy alone compared to in combination (15:36)
• T-cell targets for immunoregulatory antibody therapy; treatment for patients with underlying autoimmune disease (20:23)
• Influence of corticosteroids on immunotherapy efficacy; adverse event profiles of dabrafenib/trametinib and encorafenib/binimetinib and optimal management (25:13)
• Case: A man in his early 50s with an ulcerated melanoma metastasis and BRAF mutation (32:05)
• Case: A woman in her early 40s with BRAF-mutated melanoma and a poor ECOG performance status (41:25)

CME information and select publications